Equities research analysts expect Viking Therapeutics Inc (NASDAQ:VKTX) to report earnings per share of ($0.12) for the current quarter, Zacks reports. Zero analysts have made estimates for Viking Therapeutics’ earnings, with the highest EPS estimate coming in at ($0.10) and the lowest estimate coming in at ($0.14). Viking Therapeutics posted earnings of ($0.21) per share during the same quarter last year, which indicates a positive year over year growth rate of 42.9%. The business is expected to report its next quarterly earnings report on Wednesday, August 8th.
According to Zacks, analysts expect that Viking Therapeutics will report full-year earnings of ($0.45) per share for the current year, with EPS estimates ranging from ($0.51) to ($0.41). For the next financial year, analysts forecast that the firm will report earnings of ($0.52) per share, with EPS estimates ranging from ($0.70) to ($0.43). Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of sell-side analysts that cover Viking Therapeutics.
Viking Therapeutics (NASDAQ:VKTX) last released its quarterly earnings results on Wednesday, May 9th. The biotechnology company reported ($0.10) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.12) by $0.02.
Several equities research analysts recently issued reports on the stock. HC Wainwright set a $11.00 target price on shares of Viking Therapeutics and gave the stock a “buy” rating in a research report on Thursday, May 10th. Maxim Group set a $8.00 target price on shares of Viking Therapeutics and gave the stock a “buy” rating in a research report on Thursday, May 10th. ValuEngine raised shares of Viking Therapeutics from a “sell” rating to a “hold” rating in a research report on Monday, April 2nd. William Blair assumed coverage on shares of Viking Therapeutics in a research report on Monday, April 30th. They issued an “outperform” rating on the stock. Finally, BidaskClub cut shares of Viking Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, March 16th. One investment analyst has rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the stock. The stock has an average rating of “Buy” and an average target price of $14.25.
Shares of VKTX traded up $0.44 during mid-day trading on Friday, hitting $11.08. The company had a trading volume of 7,682,711 shares, compared to its average volume of 2,439,684. Viking Therapeutics has a 1-year low of $0.88 and a 1-year high of $13.43. The stock has a market capitalization of $626.99 million, a PE ratio of -14.03 and a beta of 2.77.
In other Viking Therapeutics news, Director J Matthew Singleton purchased 9,500 shares of Viking Therapeutics stock in a transaction on Thursday, May 31st. The shares were purchased at an average cost of $9.82 per share, with a total value of $93,290.00. Following the completion of the transaction, the director now directly owns 9,500 shares in the company, valued at approximately $93,290. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, VP Michael Morneau sold 21,551 shares of Viking Therapeutics stock in a transaction that occurred on Thursday, May 31st. The shares were sold at an average price of $9.25, for a total transaction of $199,346.75. Following the transaction, the vice president now directly owns 94,035 shares in the company, valued at $869,823.75. The disclosure for this sale can be found here. 3.90% of the stock is currently owned by company insiders.
A number of hedge funds have recently made changes to their positions in VKTX. Victory Capital Management Inc. acquired a new position in Viking Therapeutics during the fourth quarter valued at approximately $791,000. Opaleye Management Inc. acquired a new position in Viking Therapeutics during the fourth quarter valued at approximately $1,951,000. Sphera Funds Management LTD. lifted its position in Viking Therapeutics by 639.8% during the fourth quarter. Sphera Funds Management LTD. now owns 2,145,300 shares of the biotechnology company’s stock valued at $8,710,000 after buying an additional 1,855,300 shares in the last quarter. Cornerstone Capital Inc. acquired a new position in Viking Therapeutics during the fourth quarter valued at approximately $352,000. Finally, EAM Investors LLC acquired a new position in Viking Therapeutics during the fourth quarter valued at approximately $2,538,000. 41.05% of the stock is currently owned by hedge funds and other institutional investors.
Viking Therapeutics Company Profile
Viking Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead clinical program, VK5211, is an orally available, non-steroidal selective androgen receptor modulator in Phase II development for the treatment of patients recovering from non-elective hip fracture surgery; in Phase I clinical trials for improving lean body mass; and in pre-clinical trial for improving bone mineral density, bone mineral content, bone strength, and other measures.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Viking Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viking Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.